Your browser doesn't support javascript.
loading
The spectrum of mutations predisposing to familial breast cancer in Poland.
Cybulski, Cezary; Kluzniak, Wojciech; Huzarski, Tomasz; Wokolorczyk, Dominika; Kashyap, Aniruddh; Rusak, Bogna; Stempa, Klaudia; Gronwald, Jacek; Szymiczek, Agata; Bagherzadeh, Maryam; Jakubowska, Anna; Debniak, Tadeusz; Lener, Marcin; Rudnicka, Helena; Szwiec, Marek; Jarkiewicz-Tretyn, Joanna; Stawicka, Malgorzata; Domagala, Pawel; Narod, Steven A; Lubinski, Jan; Akbari, Mohammad R.
Afiliação
  • Cybulski C; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Kluzniak W; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Huzarski T; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Wokolorczyk D; Department of Clinical Genetics and Pathology, University of Zielona Góra, Zielona Góra, Poland.
  • Kashyap A; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Rusak B; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Stempa K; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Gronwald J; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Szymiczek A; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Bagherzadeh M; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, Canada.
  • Jakubowska A; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, Canada.
  • Debniak T; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Lener M; Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Rudnicka H; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Szwiec M; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Jarkiewicz-Tretyn J; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Stawicka M; Department of Surgery and Oncology, University of Zielona Góra, Zielona Góra, Poland.
  • Domagala P; Cancer Genetics Laboratory, Torun, Poland.
  • Narod SA; Department of Clinical Genetics and Pathology, University of Zielona Góra, Zielona Góra, Poland.
  • Lubinski J; Department of Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Akbari MR; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, Canada.
Int J Cancer ; 145(12): 3311-3320, 2019 12 15.
Article em En | MEDLINE | ID: mdl-31173646
ABSTRACT
To optimize genetic testing, it is necessary to establish the spectrum of breast cancer-predisposing mutations in particular ethnic groups. We studied 1,018 women with a strong family history for breast cancer (families with hereditary breast cancer; HBC) from genetically homogenous population of Poland, which is populated by ethnic Slavs, for mutations in 14 cancer susceptibility genes. Additionally, we compared the frequency of candidate pathogenic variants in breast cancer cases and controls. Germline mutations were detected in 512 of 1,018 probands with breast cancer (50.3%), including BRCA1/2 mutations detected in 420 families and non-BRCA mutations seen in 92 families. Thirteen BRCA1/2 founder mutations represented 84% of all BRCA1/2-positive cases. Seven founder mutations of CHEK2, PALB2, NBN and RECQL represented 73% of all non-BRCA-positive cases. Odds ratios for hereditary breast cancer were 87.6 for BRCA1, 15.4 for PALB2, 7.2 for CHEK2, 2.8 for NBN and 15.8 for RECQL. Odds ratios for XRCC2, BLM and BARD1 were below 1.3. In summary, we found that 20 founder mutations in six genes (BRCA1/2, CHEK2, PALB2, NBN and RECQL) are responsible for 82% of Polish hereditary breast cancer families. A simple test for these 20 mutations will facilitate genetic testing for breast cancer susceptibility in Poland. It may also facilitate genetic testing for breast cancer susceptibility in other Slavic populations and women of Slavic descent worldwide.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Mutação em Linhagem Germinativa Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Mutação em Linhagem Germinativa Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article